Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.

Item
http://www.wikidata.org/entity/Q34644867
Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial.Quality of Life and its Related Factors Among Iranian Patients with Metastatic Gastrointestinal Tract Cancer: A Cross-sectional StudyPhospholipase Cδ1 induces E-cadherin expression and suppresses malignancy in colorectal cancer cells.Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer.Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trialsObservational study on quality of life, safety, and effectiveness of first-line cetuximab plus chemotherapy in KRAS wild-type metastatic colorectal cancer patients: the ObservEr Study.Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients With Solid TumorsCetuximab concurrent with IMRT versus cisplatin concurrent with IMRT in locally advanced nasopharyngeal carcinoma: A retrospective matched case-control study.Impact of cetuximab in current treatment of metastatic colorectal cancer.Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement.Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside.How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials.Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapiesA prospective observational study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK Trial.Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial.
P2860

Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin.

Item
http://www.wikidata.org/entity/Q34644867
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@ast
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@en
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@nl
type
label
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@ast
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@en
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@nl
prefLabel
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@ast
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@en
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Quality of life analysis in pa ...... , fluorouracil and leucovorin.
@en
P2093
P304
P31
P356
10.1016/J.EJCA.2012.08.023
P433
P478
P50
P577
P5875
P698
P921